 | |
| Clinical data | |
|---|---|
| Trade names | Tessie |
| Other names | ODM-105; ODM105; ORM-19695; ORM19695 |
| Routes of administration | Dogs: Oral[1][2] Humans: unspecified[3] |
| Drug class | α2A-Adrenergic receptor agonist; Anxiolytic; Sedative; Hypnotic |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEMBL |
|
| Chemical and physical data | |
| Formula | C13H16N2O2 |
| Molar mass | 232.283 g·mol−1 |
| 3D model (JSmol) |
|
| |
| |
Tasipimidine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names ODM-105 and ORM-19695), sold under the brand name Tessie, is an α2-adrenergic receptor agonist which is approved for the short-term treatment of fear and anxiety in dogs.[1][4] It is also under development for the treatment of insomnia in humans.[2][3][5] The drug is used as an oral solution in dogs,[1] whereas its route of administration for humans is unspecified.[3]
The drug acts as a potent and selective full agonist of the human α2A-adrenergic receptor.[2] Conversely, it is a much weaker agonist of the rodent α2B-, α2C-, and α2D-adrenergic receptors.[2] In addition, it shows only low affinity for α1-adrenergic receptors, where it appears to act as a partial agonist.[2] Tasipimidine produces anxiolytic, sedative, hypolocomotor, hypotensive, and bradycardic effects in animals.[2]
Tasipimidine is under development for use in humans by Orion Corporation.[3][5] As of October 2024, it is in phase 2 clinical trials for this indication.[3][5] The drug is or was also under development for the treatment of psychiatric disorders in humans, but no recent development for this indication has been reported.[3] It has reached phase 1 trials for psychiatric disorders.[3] Tasipimidine was approved for treatment of fear and anxiety in dogs in the European Union in 2021.[1]
See also
References
- ^ a b c d "Tessie 0.3 mg/ml oral solution for dogs" (PDF). European Commission, Public Health.
- ^ a b c d e f Lehtimäki J, Jalava N, Unkila K, Aspegren J, Haapalinna A, Pesonen U (May 2022). "Tasipimidine-the pharmacological profile of a novel orally active selective α2A-adrenoceptor agonist". European Journal of Pharmacology. 923 174949. doi:10.1016/j.ejphar.2022.174949. PMID 35405115.
- ^ a b c d e f g "Tasipimidine". AdisInsight. 28 October 2024. Retrieved 2 October 2025.
- ^ Kamutzki CJ, Emmerich IU (April 2025). "[New drugs for small animals in 2024]". Tierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere (in German). 53 (2): 103–110. doi:10.1055/a-2559-6314. PMID 40233795.
- ^ a b c "Delving into the Latest Updates on Tasipimidine with Synapse". Synapse. 28 June 2025. Retrieved 3 October 2025.
